The COVID-19 pandemic had a seismic impact on the biopharma sector in 2020. Although it may be hard to remember now, biotech indices nose-dived in March of last year — but the slide was only temporary. Biotech financing set records for the remainder of the year through unprecedented fundraising and stock performances that led the bull market to record highs.
Crossover financing rounds were a leading trend in this biopharma rebound. Once a relatively uncommon strategy, they're now considered almost de rigueur before a biopharma IPO. Yet in order to structure optimum crossover rounds, biopharmas need to know which factors drive the performance of the financing itself as well as the performance of the company's subsequent IPO and share price in the market.
Join Mintz and Locust Walk for a discussion of these issues, along with the trends outlined in the recent Locust Walk white paper Crossover Evolution: The Evolving Role of the Crossover Financing Round.
Topics will include:
- How a biopharma contemplating a crossover round can optimize the process
- Whether crossover rounds typically presage successful IPOs
- How much these financing rounds boost IPO success and share
appreciation in the public markets
- Characteristics of the best crossover rounds
Speakers
Moderator, CEO & Co-Founder, Locust Walk
Principal, SR One Capital Management
Vice Chairman and Global Co-Head of Investment
Banking, SVB Leerink
Co-chair, Securities & Capital Markets Practice, Mintz
General Partner, New Enterprise Associates
When
Wednesday, May 19, 2021
1:00 – 2:00 pm ET // 10:00 – 11:00 am PT
This is an online event.